Pharmaceutical

Mr Kumar N Fadadu, Technical Manager (F&D), Vikram Ther...

FDD Conclave: Mumbai Connect | 6th March 2026 The post Mr Kumar N Fadadu, Tech...

Mr S Mukherjee, GM – Marketing, Dhara Lifescience

FDD Conclave: Mumbai Connect | 6th March 2026 The post Mr S Mukherjee, GM – Ma...

Dr Ravleen Singh Khurana, MD, Nitika Pharmaceutical Spe...

FDD Conclave: Mumbai Connect | 6th March 2026 The post Dr Ravleen Singh Khuran...

Panel Discussion: Strengthening FR&D collaboration with...

FDD Conclave: Mumbai Connect | 6th March 2026 The post Panel Discussion: Stren...

Prof Vandana B Patravale, Professor of Pharmaceutics, I...

FDD Conclave: Mumbai Connect | 6th March 2026 The post Prof Vandana B Patraval...

Panel Discussion: Building future-ready formulation teams

FDD Conclave: Mumbai Connect | 6th March 2026 The post Panel Discussion: Build...

USV launches “usema” to address India’s metabolic healt...

USV Private, an Indian multinational healthcare company and a leader in diabete...

India’s Pharma giants race to launch Semaglutide, inten...

India’s leading pharma companies have simultaneously forayed into the semagluti...

Dr Santosh Indraksha, Deputy Drugs Controller (India), ...

FDD Conclave: Mumbai Connect | 6th March 2026 The post Dr Santosh Indraksha, De...

Dr Vivek Jha, Head – R&D, Cilicant & Mr Dhairy Sharma, ...

FDD Conclave: Mumbai Connect | 6th March 2026 The post Dr Vivek Jha, Head – R&D...

Leadership Lens: Making R&D a boardroom conversation

FDD Conclave: Mumbai Connect | 6th March 2026 The post Leadership Lens: Making ...

Mr Jaynil Doshi, Director – Techno Commercial, Pioma Ch...

FDD Conclave: Mumbai Connect | 6th March 2026 The post Mr Jaynil Doshi, Directo...

BIRAC fuels innovation with Rs. 4,200 crore funding acr...

Biotechnology Industry Research Assistance Council (BIRAC), a Public Sector Ent...

Congruence secures $39.5m to advance small molecule cor...

The portfolio includes programmes targeting melanocortin 4 receptor (MC4R)-defic...

Novartis to acquire SNV4818 from Synnovation

Under the contract, Novartis will pay $2bn upfront and up to $1bn in milestones ...

Eris launches weekly shot of Semaglutide starting at ₹2...

Eris Lifesciences, a leading Indian branded formulations company, today announc...